- Ligand Reports Fourth Quarter and Full Year 2020 Financial Results
- Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
- Ligand’s Fourth Quarter Financial Results to be Reported February 3rd
- Ligand Receives Milestone Payment from Merck
- Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
Ligand Pharmaceuticals Inc (LGND:NMQ) closed at 146.34, -33.41% below its 52-week high of 219.75, set on Feb 10, 2021.
57.24Mar 17 2020219.75Feb 10 2021
Markit short selling activity
|Market cap||2.35bn USD|
|EPS (TTM)||-0.2083 |
Data delayed at least 15 minutes, as of Feb 24 2021 21:00 GMT.